Roche breast cancer drug gets FDA priority review
Vigorous exercise upregulates genes that protect against prostate CA progression
Novel drug prolongs survival in late-stage prostate cancer
Ovarian cancer screening popular despite guidelines
FDA staff unsure about new use for Amgen's Xgeva
NEW YORK (Reuters Health) - The results of a mammographic screening study suggest that some invasive breast cancers may spontaneously regress over time.
These findings "provide new insight on what is arguably the major harm associated with mammographic screening, namely, the detection and treatment of cancers that would otherwise regress," Dr. H. Gilbert Welch, from the Department of Veteran Affairs Medical Center, White River Junction, Vermont, and colleagues state.
The study, which is published in the Archives of Internal Medicine, involved 119,472 women, from 50 to 64 years of age, who underwent three rounds of mammography screening from 1996 to 2001 as part of the Norwegian Breast Cancer Screening Program. The cancer rates in this group were compared with those in 109,784 control women who would have been screened had the program been in place in 1992.
Women in the control group were invited to undergo a one-time screen at the conclusion of their observation period, the authors explain.
As anticipated, the 4-year cumulative incidence of invasive breast cancer in the screened group was higher than in the control group before screening: 1268 vs. 810 cases per 100,000 population.
However, even after the one-time screen in the control group, the 6-year cumulative incidence of breast cancer in the screened group was still higher: 1909 vs. 1564 cases per 100,000 population.
"Because the cumulative incidence among controls never reached that of the screened group, it appears that some breast cancers detected by repeated mammographic screening would not persist to be detectable by a single mammogram at the end of 6 years," Welch and colleagues conclude.
"If the 'spontaneous remission' hypothesis is credible, it should cause a major reevaluation in the approach to breast cancer research and treatment," Dr. Robert M. Kaplan, from University of California, Los Angeles, and Dr. Franz Porzsolt, from the University of Ulm, Germany, write in a related editorial. "Certainly it is worthy of further evaluation. But, finding better data to assess the hypothesis will be difficult."
Copyright © 2008 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.